Molsid is happy to announce that in May 2022 pre-clinical trials of our PYTHIA system have been conducted. PYTHIA is the first Rapid, Phenotypical AMR diagnostic test operating directly on primary clinical sample. Exceptional results have been obtained in collaboration with Prof. Laurent Poirel in Fribourg university hospitals, Switzerland.
Extraordinary specificity has been observed for 14 out of 15 enzyme activities detected. This corresponds to 98% of the 2020 EU AMR cases.
Unprecedented detection sensitivity and quantitation of most enzyme activities allowed us to even determine bacterial counts as low as 1.000 to 10.000 bacteria/mL.
Recent posts
It was a pleasure for MOLSID, represented by its Executive Director Younes Lazrak, to present our product pipeline at this year’s ESCMID GLOBAL. Many thanks
A new fundraising round has been opened and will close in Q1 2024, with existing and new investors. This round will allow us to speed
We have updated our corporate clip. Have a look to learn more about who we are and what we do!
Get in touch
Technologie
Applications
Company
